article · QJM
Abstract Background Cerebral small vessel disease (CSVD) is associated with increased risk of death and ischemic stroke in patients with atherosclerotic disease. Identifying new biomarkers is mandatory for early diagnosis and proper management. Aim of the Study The aim of this study is to investigate the role of serum complement C1q as a potential biomarker for early diagnosis of CSVD in a sample of Egyptian patients. Patients and Methods 30 patients with CVSD and 20 healthy volunteers who were matched for age and sex were recruited. Serum complement C1q was determined by ELISA according to manufacturer instructions. Results Serum C1q levels were significantly higher in CVSD patients compared to healthy controls. On the other hand, serum C1q levels were not significantly correlated with clinical symptoms or radiological findings in this population. Conclusion Complement C1q may play a role in pathogenesis of incidental cerebral small vessel disease and warrants further studies.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1093/qjmed/hcae175.182
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.